340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

Mylan EpiPen Settlement Provides for 340B Overcharging Claims


 

Print Article

August 17, 2017—The U.S. Justice Department, CMS, and EpiPen manufacturer Mylan announced today that Mylan has reached a $465 million settlement with the government to resolve claims it knowingly misclassified EpiPen as a generic drug to avoid paying Medicaid drug rebates.

Mylan said the settlement provides for “potential claims by certain hospitals and other covered entities that participate in the 340B Drug Pricing Program.” There were no further details.

CMS said “Mylan will reclassify EpiPen as a brand name drug consistent with the Medicaid statute and regulations. In addition, Mylan has agreed to use the correct reference price of the 3rd quarter of 1990 for the purpose of calculating inflationary payment rebates under the Medicaid Drug Rebate (MDR) program, saving the Medicaid program hundreds of millions of dollars. These changes will be effective retroactive to April 1, 2017.”

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health